



LiteVax receives EU Horizon 2020 grant for the development of a next generation of flu vaccines for the globe

Oss, The Netherlands, April, 2020 – A consortium of public and private R&D organisations from EU, India, and US has been awarded a 10 m€ grant for development of improved influenza virus vaccines for the globe. Later this year, this grant will be matched by the government of India. LiteVax BV (Oss, The Netherlands) and the Translational Health Science Technology Institute (Delhi, India) have initiated the project and the University of Amsterdam will be the coordinator. The INDIGO project builds on LiteVax’s patented, versatile adjuvant technology developed to improve prophylactic and therapeutic vaccines.

The grant will support the development of a next generation of influenza vaccines aiming at higher effectivity, lower costs and better accessibility. The INDIGO project combines innovations in antigen design, antigen delivery and immune-stimulation and plans to perform phase I/IIa clinical trials in EU and India.

In addition to LiteVax, the INDIGO consortium consists of one Danish partner, two Belgian partners, three French partners, two Dutch partners, one US partner, and six Indian partners. An important goal is the collaboration between R&D organizations in these countries with complementary skills and know-how. See <https://cordis.europa.eu/project/id/874653> for more information.

LiteVax CEO Luuk Hilgers comments:

“In these unprecedented pandemic times we must not forget that common flu is still a very serious disease. According to the WHO there are yearly 1 billion cases, 3-5 million severe cases and 290,000-650,000 influenza-related casualties worldwide. Through the grants, this EU-India-US consortium will be able to work closely to deliver a next-generation of flu vaccines that addresses a worldwide medical need.”

The initial work plan may be delayed by the current COVID-19 pandemic.

For further information about LiteVax, please contact:

Luuk Hilgers, CEO

Telephone: +31 6 2336 7812

E-mail: luuk.hilgers@litevax.com

About LiteVax

LiteVax BV is a Dutch biopharmaceutical SME with the mission to impact global health by developing and exploiting novel immunoadjuvants to increase vaccine efficacy. New and more effective vaccines against a wide range of infectious diseases are needed as evidenced by the recent outbreaks. The adjuvant technology is the missing link between promising concepts and viable products. Litevax has collaborations with several public and private vaccine R&D organizations world-wide.

Half of the volume of vaccines applied world-wide is manufactured in India. The country has know-how and infrastructure to develop state-to-the-art products and private companies with the ambitions to develop and commercialize new vaccines for domestic and foreign markets. This makes India attractive for partnering the versatile adjuvant technology.